Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.43 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.42 |
| ▸ | TPH1 | P17752 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548420 | 0.88 | HCAR2 (0.43) | HCAR2FFAR1PPARDPPARANPC1 | |
| SCHEMBL17253033 | 0.85 | RAB9A (0.53) | PPARDPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13933888 | 0.83 | PPARD (0.44) | HCAR2FFAR1PPARDPPARANPC1 | |
| SCHEMBL13933895 | 0.83 | PPARD (0.42) | HCAR2PPARDPPARANPC1RAB9A | |
| SCHEMBL4548428 | 0.81 | HCAR2 (0.66) | HCAR2PPARDPPARA | |
| SCHEMBL4548432 | 0.80 | HCAR2 (0.49) | HCAR2FFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1568004 | 0.79 | LMNA (0.65) | FFAR1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL4548463 | 0.76 | CYP4F2 (0.53) | HCAR2FFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4548429 | 0.75 | MAOB (0.46) | HCAR2FFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4548476 | 0.74 | LMNA (0.52) | FFAR1NPC1RAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | HCAR2 2/4885FFAR1 4/4885PPARD 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.